Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655207 · ClinicalTrials.gov registry record · NA
Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage
A NA study of High Risk Pregnancy and Maternal Care Patterns, sponsored by Baymatob Operations Pty.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 7
- Study locations
NCT06655207: Recruiting NA study of High Risk Pregnancy and Maternal Care Patterns, sponsored by Baymatob Operations Pty.
NCT06655207 is a NA study of High Risk Pregnancy and Maternal Care Patterns that is actively recruiting participants, run by Baymatob Operations Pty. The registered enrollment target is 1,000 participants, above the 228-participant average among 10 other High Risk Pregnancy trials with a reported enrollment target (339% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06655207, a NA study of High Risk Pregnancy and Maternal Care Patterns, is actively recruiting participants, sponsored by Baymatob Operations Pty.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
Oli is a predictive, non-invasive device, intended to be placed on the participant's maternal abdomen during the intrapartum period, which can alert healthcare professionals of an impending cumulative blood loss of ≥500 ml (abnormal postpartum uterine bleeding) or cumulative blood loss of ≥1000ml (postpartum haemorrhage) at least 1 hour in advance of birth. This study is being undertaken to assess the performance of Oli measuring cumulative blood loss ≥500ml and ≥1000ml, as well as evaluate its safety profile.
Conditions Studied
Interventions
- DEVICE Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Study Locations (7)
New South Wales
- Royal Hospital for Women - Randwick
- Royal North Shore Hospital - St Leonards
Colorado
- UC Health University of Colorado Hospital - Denver
Louisiana
- Woman's Hospital - Baton Rouge
New York
- Columbia University Irving Medical Center - New York
Ohio
- The Ohio State University - Columbus
Pennsylvania
- UPMC Magee Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2026-07-30 |
| Phase | NA |
What NCT06655207 shows while recruiting
NCT06655207 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 228-participant average among 10 other High Risk Pregnancy trials with a reported enrollment target (339% higher).
The record links to 3 conditions, with High Risk Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding is the first listed.
NCT06655207 lists 7 locations in 6 states (New South Wales, Colorado, Louisiana).
Frequently Asked Questions
What is clinical trial NCT06655207 about?
NCT06655207 is a clinical study titled "Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage". Oli is a predictive, non-invasive device, intended to be placed on the participant's maternal abdomen during the intrapartum period, which can alert healthcare professionals of an impending cumulative blood loss of ≥500 ml (abnormal postpartum uterine bleeding) or cumulative blood loss of ≥1000ml (p...
What is the current status of trial NCT06655207?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-08-06. Estimated completion is 2026-07-30.
What conditions does trial NCT06655207 study?
This clinical trial studies the following conditions: High Risk Pregnancy, Maternal Care Patterns, Post Partum Haemorrhage.
What interventions are being tested in trial NCT06655207?
The interventions under investigation include: Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding (DEVICE).
Who is sponsoring clinical trial NCT06655207?
This trial is sponsored by Baymatob Operations Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06655207 being conducted?
This trial has 7 study locations across Colorado, Louisiana, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Risk Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06655207's enrollment target sits among peer trials
1,000 1st of 10 the highest of 10 other High Risk Pregnancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Risk Pregnancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preventing Obstetric Complications With Dietary Intervention
RECRUITING · NA
-
Leg Heating in Pregnant Women With Obesity
RECRUITING · NA
-
The Impact of Arts-Based Interventions on Patient Hospital Experience
COMPLETED · NA
-
Misoprostol With Mechanical Dilation Versus Oxytocin With Mechanical Dilation for High-risk Pregnancy Inductions
COMPLETED · NA
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
Remote Fetal Monitoring in High Risk Pregnancies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI